Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,45
KB-0,12
PKN67,4567,482,74
Msft414,33414,39-0,12
Nokia3,1593,1625-0,05
IBM183,51183,55-0,11
Mercedes-Benz Group AG74,3674,38-0,32
PFE25,3225,33-1,40
17.04.2024 17:21:56
Indexy online
AD Index online
select
AD Index online
 

  • 17.04.2024 17:20:44
Ipsen (IPN.PA, Paris)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
106,70 -0,84 -0,90 3 567 293
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 17.04.2024
Popis společnosti
Obecné informace
Název společnostiIpsen SA
TickerIPN
Kmenové akcie:Ordinary Shares
RICIPN.PA
ISINFR0010259150
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2022 5 072
Akcie v oběhu k 31.12.2023 82 639 241
MěnaEUR
Kontaktní informace
Ulice65 Quai Georges Gorse
MěstoBOULOGNE-BILLANCOURT
PSČ92100
ZeměFrance
Kontatní osobaCraig Marks
Funkce kontaktní osobyVice President, Investor Relations
Telefon33 158 335 000
Fax33158335001
Kontatní telefon447 584 349 193

Business Summary: Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Ipsen SA revenues increased 5% to EUR3.31B. Net income before extraordinary items increased 4% to EUR617.1M. Revenues reflect Turnover increase of 3% to EUR3.13B, Other revenues increase of 36% to EUR178.9M. Net income was partially offset by Research and development expenses increase of 39% to EUR619.3M (expense), Other operating expenses increase of 49% to EUR453.3M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 17.04.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardMarc De Garidel6518.07.201622.11.2010
Chief Executive Officer, DirectorDavid Loew5601.07.202001.07.2020
Vice Chairman of the BoardAntoine Flochel5830.08.200530.08.2005
Chief Financial Officer, Executive Vice PresidentAymeric Le Chatelier-01.07.202003.11.2014
Chief Human Resource Officer, Executive Vice PresidentRegis Mulot5713.03.201813.03.2018
Executive Vice President, General Counsel, Chief Business Ethics OfficerFrancois Garnier6101.01.2015
Executive Vice President, Strategy, Transformation and DigitalCatherine Abi-habib-01.01.2022
Executive Vice President, Head of Global Product and Portfolio StrategyBartosz Bednarz-01.01.2020
Executive Vice President, President of Ipsen North AmericaStewart Campbell-03.11.202103.11.2021
Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients AffairsSteven Hildemann6101.03.202001.03.2020